Paige AI (Tempus AI)

Paige AI is a global pioneer in computational pathology and artificial intelligence designed to transform cancer diagnostics and biomarker discovery. Originally spun out of Memorial Sloan Kettering Cancer Center and subsequently acquired by Tempus AI, the platform acts as an intelligent system of action for modern laboratories. Paige converts standard glass tissue slides into high-resolution Whole Slide Images (WSIs) and processes them through deep learning models trained on millions of uncurated slides. This framework optimizes pathologist workflows, significantly mitigates human diagnostic error, and surfaces advanced predictive insights that are invisible to the human eye.

The company provides a wide array of disease-specific, clinically validated AI software targeting critical oncology pipelines:

Paige Prostate Suite: Features Paige Prostate Detect—the industry's first FDA-authorized AI tool for primary prostate cancer diagnosis—which delivers a 70% reduction in diagnostic errors and up to a 65% reduction in turnaround times. It includes automated grading (Gleason patterns) and tumor quantification.

Paige Breast Suite: Provides automated detection of breast carcinomas, identifies individual mitotic figures, maps high-density hotspots, and detects subtle metastases within complex lymph node specimens.

Paige GI Suite: Assists pathologists in identifying, localizing, and subtyping neoplasms, carcinomas, and high-grade dysplasia across the entire gastrointestinal tract.

Paige PanCancer Suite: An FDA Breakthrough-designated AI tool capable of triaging and identifying regions of structural suspicion across dozens of diverse tissue types.

Beyond daily clinical diagnostics, Paige is a leader in clinical foundation models, including the industry-standard Virchow family (Virchow, Virchow 2, Virchow 2G) and PRISM. These massive, multi-tissue transformer models eliminate the tedious, resource-heavy task of training narrow, single-purpose AI from scratch. Biopharmaceutical companies and researchers leverage these pre-trained architectures to rapidly accelerate drug development pipelines. Furthermore, tools like Paige OmniScreen⁺ act as next-generation pre-screening assays, predicting the status of roughly 1,600 biomarkers across 505 genes directly from a single, standard H&E slide in under 5 minutes—sparing precious patient tissue and accelerating clinical trial enrollment.

Paige Alba™ is the platform's proprietary generative AI co-pilot, designed to revolutionize how pathologists interact with technology via intuitive voice and text commands. Pathologists can query Alba for real-time diagnostic insights, differential data, and workflow support during live slide evaluation. The entire Paige ecosystem is engineered with a 100% vendor-agnostic architecture. Labs can access these tools natively through the Paige Platform—featuring the FDA-cleared FullFocus® slide viewer and FullFolio™ case management software—or deploy them seamlessly into their existing third-party image management systems (IMS) and scanner hardware without technical disruption.